来自官方财务报表的收入、利润与现金流历史。
Qiagen N.V. 提供从样本到洞察的解决方案，将全球范围内的生物样本转化为分子洞察。该公司提供样品技术耗材，例如用于样品材料的核酸稳定和纯化试剂盒、用于基因分型、基因表达以及病毒和细菌分析的手动和自动处理，以及硅胶膜和磁珠技术；二次样品技术耗材，包括用于纯化核酸的试剂盒和组件；以及核酸纯化、质量控制仪器和配件。它还提供免疫反应耗材，例如用于结核病检测的干扰素γ释放测定，以及用于移植后检测和病毒载量监测的测定；肿瘤学以及性健康和生殖健康消耗品，包括产前检测以及性传播疾病和 HPV 检测的化验；用于分析基因组变异的测定；以及从样本到洞察仪器，包括难以诊断综合征的一步分子分析和集成 PCR 检测。该公司提供研究型 PCR 耗材，例如定量 PCR、逆转录以及用于分析基因表达、基因分型和基因调控的组合试剂盒，并在 QIAGEN 仪器和技术上运行；人类身份/法医分析耗材，包括人类身份短串联重复分析和食品污染分析； PCR仪器，包括数字PCR和qPCR解决方案；并开发和配置酶和 PCR 解决方案。它提供NGS基因panel、文库制备试剂盒和组件以及全基因组扩增； DNA甲基化分析； QIAGEN 耗材和仪器；生物信息学解决方案；和基于序列的法医遗传谱系服务。我
机器翻译
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $2.1B | $2.1B | $2.0B | $2.0B | $2.1B | $2.3B | $1.9B | $1.5B | $1.5B | $1.4B | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B | $1.2B | $1.1B | $1.0B | $893M | $650M | $466M |
| 毛利 | $1.3B | $1.3B | $967M | $1.2B | $1.4B | $1.5B | $1.2B | $1.0B | $1.0B | $923M | $845M | $827M | $865M | $815M | $824M | $750M | $716M | $667M | $600M | $434M | $325M |
| 毛利率% | 61.8% | 61.8% | 48.9% | 62.8% | 64.6% | 64.4% | 65.9% | 65.9% | 66.6% | 65.1% | 63.1% | 64.5% | 64.3% | 62.6% | 65.7% | 64.1% | 65.8% | 66.1% | 67.2% | 66.7% | 69.7% |
| 营业利润（EBIT） | — | $520M | $98M | $410M | $531M | $630M | $386M | ($26M) | $267M | $153M | $99M | $179M | $162M | $63M | $170M | $100M | $189M | $180M | $146M | $83M | $101M |
| 营业利润率% | — | 24.9% | 4.9% | 20.9% | 24.8% | 28.0% | 20.7% | -1.7% | 17.8% | 10.8% | 7.4% | 14.0% | 12.0% | 4.9% | 13.5% | 8.5% | 17.3% | 17.8% | 16.3% | 12.8% | 21.6% |
| 净利 | $409M | $425M | $84M | $341M | $423M | $513M | $359M | ($41M) | $190M | $40M | $80M | $130M | $116M | $69M | $130M | $96M | $144M | $138M | $89M | $50M | $71M |
| 净利润率 % | 19.5% | 20.3% | 4.2% | 17.4% | 19.8% | 22.8% | 19.2% | -2.7% | 12.7% | 2.9% | 6.0% | 10.2% | 8.6% | 5.3% | 10.3% | 8.2% | 13.3% | 13.6% | 10.0% | 7.7% | 15.1% |
| EBITDA | — | $717M | $368M | $689M | $779M | $895M | $716M | $228M | $499M | $381M | $309M | $365M | $360M | $268M | $366M | $289M | $344M | $322M | $263M | $195M | $140M |
| 每股收益（EPS） | $1.95 | $2.04 | $0.38 | $1.57 | $1.90 | $2.28 | $1.58 | $-0.19 | $0.82 | $0.17 | $0.35 | $0.57 | $0.50 | $0.30 | $0.56 | $0.42 | $0.62 | $0.67 | $0.45 | $0.30 | $0.48 |
| 已发行股数 (M) | — | 208M | 218M | 217M | 223M | 225M | 227M | 220M | 233M | 233M | 230M | 228M | 233M | 233M | 232M | 230M | 232M | 206M | 197M | 169M | 148M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 QGEN 交互式查看器。 /companies/us/QGEN
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms